Salesforce, Inc.

Executive Summary

BUY, Medium conviction. Rated BUY, Medium conviction. CRM offers an unusual mix of scale, improving growth, and discounted valuation, with FY27 revenue guided to $45.8B-$46.2B, CRPO up 16%, and AI products already monetizing through ~$800M Agentforce ARR and $2.9B Agentforce/Data 360 ARR. The stock has already rallied 58.41% in 3 months and sits 11.6% below its 52-week high, so this is no longer an early trade, but valuation still does not fully reflect a business moving back toward double-digit growth with expanding strategic relevance.

Investment Thesis

The market is still paying for Salesforce as if it were a slower, ex-growth application software incumbent. That no longer fits the numbers. FY2026 revenue grew 6.0% to $41.5B, but the exit rate is better than the full-year average: Q4 revenue was $11.2B, up 12% YoY, CRPO reached $35.1B, up 16%, and management guided FY27 revenue to $45.8B-$46.2B, or about 10% to 11% growth. That matters because the stock still trades at only 21.63x earnings and 4.44x sales, both well below peer averages of 34.7x and 8.6x.

The core of the case is that AI is becoming a revenue accelerator, not just a demo. Management said, "We have found the formula to monetize AI." That claim is backed by operating evidence: Agentforce ARR ~ $800M, up 169% YoY, Agentforce/Data 360 ARR at $2.9B, up 200% YoY, premium Agentforce bookings nearly tripled QoQ, and every top 10 win included Agentforce. Informatica also appears to be strengthening the data foundation rather than just adding inorganic noise, contributing $1.1B cloud ARR and showing up in 6 of the top 10 wins. If AI spend in enterprise software consolidates around platforms with trusted customer data and embedded workflow, Salesforce is one of the few scaled beneficiaries.

The second leg of the thesis is management execution. The last seven quarterly EPS reports all beat, often by a lot, including +80.4%, +24.0%, +24.9%, and +13.6%. That does not guarantee upside, but it does support giving management more credit when they guide H2 reacceleration. Robin Washington said, "We are initiating fiscal year '27 revenue guidance of $45.8 billion to $46.2 billion, growth of approximately 10% to 11% in nominal and constant currency." Miguel Milano added, "Today, we are saying that the revenue reacceleration, organic revenue acceleration of subscription and support is going to happen in H2."

What keeps conviction at Medium instead of High is the setup and the balance sheet. The stock is already 58.41% above where it was 3 months ago and sits just 11.6% below its 52-week high, so a lot of the narrative repair is priced. The company is also funding growth with only 20 bps of non-GAAP margin expansion guided for FY27, while leverage sits at 3.17x Debt/EBITDA. This is still a buy, but it is a buy on continued proof, not on hope.

Key Metrics

Financial Strength

The balance-sheet read is mixed, not weak. Salesforce still has the margin structure of a very good software business, with FY2026 net margin at 16.4%, flat FY operating margin at 19.0%, and FY27 GAAP operating margin guided up to 20.9% even while investing in Hyperforce, sales capacity, and headcount. Cash flow quality is excellent at 95/100, which helps explain why the company can support a $50B buyback and higher dividend. The issue is leverage and near-term flexibility: Debt/EBITDA 3.17x, Debt/Equity 1.09, and a 0.84 current ratio are fine for a large recurring-revenue platform, but not so clean that investors should ignore execution risk if AI-related investment takes longer to monetize.

Competitive Position

Salesforce's moat remains rooted in distribution, embedded workflows, and customer data that sit inside day-to-day sales, service, and marketing processes. That moat looks stronger today than it did a year ago because AI is amplifying the value of system-of-record software, not bypassing it, and CRM has proof that Agentforce is being sold with core clouds, data, analytics, and platform products rather than as a sidecar. The most important evidence is commercial, not conceptual: all top 10 wins included Agentforce, Informatica appeared in 6 of the top 10 wins, and larger deals accelerated with $10M+ wins up 33% YoY. The weaker pockets, especially Tableau and parts of Marketing and Commerce, mean the moat is not uniform across the portfolio, but the core franchise is still one of the few enterprise stacks with the data gravity to monetize AI at scale.

Management & Guidance

Management is guiding from a position of improving demand, not financial engineering. The FY27 revenue outlook of $45.8B-$46.2B implies a clear growth step-up, and management explicitly tied that to H2 subscription and support reacceleration. Robin Washington said, "Our non-GAAP operating margin guidance is 34.3%, an expansion of 20 basis points." That limited margin upside lowers the chance that guidance is inflated by underinvestment, which actually adds credibility. Execution history also supports a constructive read: Salesforce delivered seven straight EPS beats after one modest miss in late 2024, including a +80.4% beat in August 2026. The caution is that some weaker businesses, notably Tableau, Marketing, Commerce, and on-prem-exposed MuleSoft timing, still need to improve for the raised FY30 target to feel fully de-risked.

Bull Case

• Demand indicators improved materially: Q4 revenue $11.2B, +12% YoY, CRPO $35.1B, +16% YoY, and Q1 FY27 CRPO growth guided to ~14% YoY, supporting management's call for H2 acceleration.
• Management is finally monetizing AI at scale, with all top 10 wins including Agentforce, premium Agentforce bookings nearly tripling QoQ, and deals above $10M up 33% YoY in Q4.
• Profitability is holding despite investment: FY27 non-GAAP operating margin is guided to 34.3%, GAAP operating margin to 20.9%, and Q4 EBITDA margin reached 33.5%, up 200 bps YoY.
• Capital allocation has become more shareholder-friendly, with a $50B buyback authorization and a 5.8% dividend increase to $0.44/share, while the stock still trades at a discount to software peers.

Bear Case

• The stock is no longer washed out after a 58.41% move in 3 months and now trades 18.0% above its 200-day average, which raises the bar for the December 2 print.
• Balance-sheet flexibility is not pristine, with Debt/EBITDA 3.17, Debt/Equity 1.09, and a 0.84 current ratio, limiting room for execution mistakes if growth investments take longer to pay back.
• FY27 margin expansion is light at just 20 bps on the non-GAAP operating line, despite stronger growth, because Hyperforce, sales capacity, and headcount investment are ramping.
• Not all franchises are participating: Marketing and Commerce remained weak, while Tableau underperformed expectations and MuleSoft saw on-prem timing pressure.

Valuation & Price Target

Engine price target $331.86 (+39.5% vs current), Low confidence.

• P/E Multiple: $491.63 (24% weight)
• PEG (growth-adjusted): $132 (20% weight)
• P/S Multiple: $488.36 (18% weight)
• Quality-adjusted: $272.18 (20% weight)
• DCF: $218.21 (12% weight)

The rating stays aligned with the quant baseline BUY, but with Medium rather than low conviction because the operating setup is improving faster than the low-confidence valuation blend captures. The quant price target is $331.86, based on a wide spread between $132 on PEG and roughly $488-$492 on P/E and P/S methods, which reflects real uncertainty around how durable this reacceleration is. That uncertainty is fair given the 5.6x peer P/E dispersion and the fact that CRM's own weaker assets, especially Marketing, Commerce, and Tableau, still need work. Even so, the combination of 10% to 11% FY27 revenue growth, 16% CRPO growth, and a trailing 21.63x P/E supports staying positive. Sell-side consensus is also bullish, but that is context, not the reason for the call.

Risk Assessment

Risk score 34/100 (Low). The biggest risk is that AI-led demand proves narrower than current bookings suggest, because CRM is investing against FY27 growth while guiding only 20 bps of non-GAAP margin expansion and carrying 3.17x Debt/EBITDA.

The Bottom Line

CRM rates a BUY at Medium conviction. The stock is no longer cheap on sentiment after a sharp rally, but it is still cheap on fundamentals if FY27 growth and AI monetization continue on the current path. The main reason to own it here is that the market still discounts the durability of a business now guiding back to 10% to 11% growth with visible AI traction. A move toward the quant $331.86 target is plausible if December earnings confirm CRPO strength and H2 acceleration. The call would turn less positive if AI ARR growth slows materially, if CRPO loses momentum from the current 16% pace, or if margin discipline slips without a matching revenue payoff.